{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T10:25:39Z","timestamp":1794565539011,"version":"4.9.1"},"reference-count":78,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100015496","name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red sobre Enfermedades Neurodegenerativas","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100015496","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003339","name":"Spanish National Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002911","name":"Universidad Complutense de Madrid","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002911","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008049","name":"Santander Bank Foundation","doi-asserted-by":"publisher","award":["PR44\/21-29931"],"award-info":[{"award-number":["PR44\/21-29931"]}],"id":[{"id":"10.13039\/100008049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003329","name":"Ministerio de Econom\u00eda y Competitividad","doi-asserted-by":"publisher","award":["SAF2017-85199-P"],"award-info":[{"award-number":["SAF2017-85199-P"]}],"id":[{"id":"10.13039\/501100003329","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Neurology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.expneurol.2026.115822","type":"journal-article","created":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T23:05:15Z","timestamp":1778627115000},"page":"115822","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Therapeutic properties of ayahuasca component N,N-Dimethyltryptamine in a pre-clinical model of Parkinson's disease"],"prefix":"10.1016","volume":"403","author":[{"given":"Javier","family":"Calleja-Conde","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00edctor","family":"Echeverry-Alzate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Sanz-SanCristobal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Alonso-Gil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Gin\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kora","family":"B\u00fchler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose A.","family":"L\u00f3pez-Moreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Perez-Castillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 A.","family":"Morales-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.expneurol.2026.115822_bb0005","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1038\/s41593-025-02021-1","article-title":"The psychoplastogen tabernanthalog induces neuroplasticity without proximate immediate early gene activation","volume":"28","author":"Aarrestad","year":"2025","journal-title":"Nat. Neurosci."},{"issue":"1","key":"10.1016\/j.expneurol.2026.115822_bb0010","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/nrn2038","article-title":"Microglia-mediated neurotoxicity: uncovering the molecular mechanisms","volume":"8","author":"Block","year":"2007","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.expneurol.2026.115822_bb0015","doi-asserted-by":"crossref","first-page":"290","DOI":"10.3389\/fnbeh.2014.00290","article-title":"A mouse model of non-motor symptoms in Parkinson's disease: focus on pharmacological interventions targeting affective dysfunctions","volume":"8","author":"Bonito-Oliva","year":"2014","journal-title":"Front. Behav. Neurosci."},{"issue":"9","key":"10.1016\/j.expneurol.2026.115822_bb0020","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.biopsych.2013.02.015","article-title":"Cognitive impairment and dentate gyrus synaptic dysfunction in experimental parkinsonism","volume":"75","author":"Bonito-Oliva","year":"2014","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.expneurol.2026.115822_bb0025","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.neuroscience.2011.10.057","article-title":"Neurotoxin-based models of Parkinson's disease","volume":"211","author":"Bove","year":"2012","journal-title":"Neuroscience"},{"issue":"1\u20133","key":"10.1016\/j.expneurol.2026.115822_bb0030","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.ejphar.2006.09.038","article-title":"Interactions between 3,4-methylenedioxymethamphetamine and sigma1 receptors","volume":"553","author":"Brammer","year":"2006","journal-title":"Eur. J. Pharmacol."},{"issue":"5","key":"10.1016\/j.expneurol.2026.115822_bb0035","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1111\/acer.14321","article-title":"Inhibition of receptor protein tyrosine phosphatase beta\/zeta reduces alcohol intake in rats","volume":"44","author":"Calleja-Conde","year":"2020","journal-title":"Alcohol. Clin. Exp. Res."},{"issue":"2","key":"10.1016\/j.expneurol.2026.115822_bb0040","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1080\/02791072.2020.1718250","article-title":"Psychedelic microdosing: prevalence and subjective effects","volume":"52","author":"Cameron","year":"2020","journal-title":"J. Psychoactive Drugs"},{"issue":"7842","key":"10.1016\/j.expneurol.2026.115822_bb0045","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1038\/s41586-020-3008-z","article-title":"A non-hallucinogenic psychedelic analogue with therapeutic potential","volume":"589","author":"Cameron","year":"2021","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.expneurol.2026.115822_bb0050","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s13195-024-01462-3","article-title":"N, N-dimethyltryptamine, a natural hallucinogen, ameliorates Alzheimer\u2019s disease by restoring neuronal Sigma-1 receptor-mediated endoplasmic reticulum-mitochondria crosstalk","volume":"16","author":"Cheng","year":"2024","journal-title":"Alzheimer\u2019s Res. Ther."},{"issue":"9916","key":"10.1016\/j.expneurol.2026.115822_bb0055","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S0140-6736(13)62106-6","article-title":"Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial","volume":"383","author":"Cummings","year":"2014","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.expneurol.2026.115822_bb0060","doi-asserted-by":"crossref","DOI":"10.3390\/genes12071006","article-title":"The genetics of Parkinson\u2019s disease and implications for clinical practice","volume":"12","author":"Day","year":"2021","journal-title":"Genes (Basel)"},{"issue":"11","key":"10.1016\/j.expneurol.2026.115822_bb0065","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1016\/0006-2952(91)90178-8","article-title":"Differential interactions of dimethyltryptamine (DMT) with 5-HT1A and 5-HT2 receptors","volume":"41","author":"Deliganis","year":"1991","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.expneurol.2026.115822_bb0070","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.arr.2017.12.007","article-title":"The genetics of Parkinson disease","volume":"42","author":"Deng","year":"2018","journal-title":"Ageing Res. Rev."},{"issue":"10","key":"10.1016\/j.expneurol.2026.115822_bb0075","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.1111\/j.1460-9568.2003.03014.x","article-title":"Microglial activation with atypical proinflammatory cytokine expression in a rat model of Parkinson\u2019s disease","volume":"18","author":"Depino","year":"2003","journal-title":"Eur. J. Neurosci."},{"issue":"1","key":"10.1016\/j.expneurol.2026.115822_bb0080","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1590\/1516-4446-2015-1701","article-title":"Antidepressive and anxiolytic effects of Ayahuasca: a systematic literature review of animal and human studies","volume":"38","author":"Dos Santos","year":"2016","journal-title":"Braz. J. Psychiatry."},{"issue":"9","key":"10.1016\/j.expneurol.2026.115822_bb0085","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1080\/17512433.2018.1511424","article-title":"Efficacy, tolerability, and safety of serotonergic psychedelics for the management of mood, anxiety, and substance-use disorders: a systematic review of systematic reviews","volume":"11","author":"Dos Santos","year":"2018","journal-title":"Expert. Rev. Clin. Pharmacol."},{"issue":"1\u20132","key":"10.1016\/j.expneurol.2026.115822_bb0090","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.neuropharm.2010.03.013","article-title":"5-HT2A receptor antagonists improve motor impairments in the MPTP mouse model of Parkinson\u2019s disease","volume":"59","author":"Ferguson","year":"2010","journal-title":"Neuropharmacology"},{"issue":"5916","key":"10.1016\/j.expneurol.2026.115822_bb0095","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1126\/science.1166127","article-title":"The hallucinogen N,N-dimethyltryptamine (DMT) is an endogenous sigma-1 receptor regulator","volume":"323","author":"Fontanilla","year":"2009","journal-title":"Science"},{"key":"10.1016\/j.expneurol.2026.115822_bb0100","series-title":"Paxinos and Franklin\u2019s the Mouse Brain in Stereotaxic Coordinates","author":"Franklin","year":"2013"},{"issue":"9","key":"10.1016\/j.expneurol.2026.115822_bb0105","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1007\/s00702-013-1024-y","article-title":"A possibly sigma-1 receptor mediated role of dimethyltryptamine in tissue protection, regeneration, and immunity","volume":"120","author":"Frecska","year":"2013","journal-title":"J. Neural Transm. (Vienna)"},{"issue":"12","key":"10.1016\/j.expneurol.2026.115822_bb0110","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1038\/81737","article-title":"A new link between pesticides and Parkinson\u2019s disease","volume":"3","author":"Giasson","year":"2000","journal-title":"Nat. Neurosci."},{"issue":"6","key":"10.1016\/j.expneurol.2026.115822_bb0115","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/j.cell.2010.02.016","article-title":"Mechanisms underlying inflammation in neurodegeneration","volume":"140","author":"Glass","year":"2010","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.expneurol.2026.115822_bb0120","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.neuron.2007.01.008","article-title":"Hallucinogens recruit specific cortical 5-HT(2A) receptor-mediated signaling pathways to affect behavior","volume":"53","author":"Gonzalez-Maeso","year":"2007","journal-title":"Neuron"},{"issue":"2\u20133","key":"10.1016\/j.expneurol.2026.115822_bb0125","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.mvr.2007.05.006","article-title":"In vitro assays of angiogenesis for assessment of angiogenic and anti-angiogenic agents","volume":"74","author":"Goodwin","year":"2007","journal-title":"Microvasc. Res."},{"issue":"7","key":"10.1016\/j.expneurol.2026.115822_bb0130","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.amjmed.2019.03.001","article-title":"Parkinson\u2019s disease and parkinsonism","volume":"132","author":"Hayes","year":"2019","journal-title":"Am. J. Med."},{"key":"10.1016\/j.expneurol.2026.115822_bb0135","first-page":"277","article-title":"Effect of ritanserin, a highly selective 5-HT2 receptor antagonist, on Parkinson\u2019s disease","volume":"29","author":"Henderson","year":"1992","journal-title":"Clin. Exp. Neurol."},{"issue":"4","key":"10.1016\/j.expneurol.2026.115822_bb0140","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/S1474-4422(09)70062-6","article-title":"Neuroinflammation in Parkinson\u2019s disease: a target for neuroprotection?","volume":"8","author":"Hirsch","year":"2009","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.expneurol.2026.115822_bb0145","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1111\/j.1749-6632.2003.tb07478.x","article-title":"The role of glial reaction and inflammation in Parkinson\u2019s disease","volume":"991","author":"Hirsch","year":"2003","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"Suppl. 1","key":"10.1016\/j.expneurol.2026.115822_bb0150","doi-asserted-by":"crossref","first-page":"S210","DOI":"10.1016\/S1353-8020(11)70065-7","article-title":"Neuroinflammation in Parkinson\u2019s disease","volume":"18","author":"Hirsch","year":"2012","journal-title":"Parkinsonism Relat. Disord."},{"issue":"9","key":"10.1016\/j.expneurol.2026.115822_bb0155","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1177\/0269881119857204","article-title":"Microdosing psychedelics: more questions than answers? An overview and suggestions for future research","volume":"33","author":"Kuypers","year":"2019","journal-title":"J. Psychopharmacol."},{"issue":"3","key":"10.1016\/j.expneurol.2026.115822_bb0160","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24031971","article-title":"Overview of sigma-1R subcellular specific biological functions and role in neuroprotection","volume":"24","author":"Lachance","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"5","key":"10.1016\/j.expneurol.2026.115822_bb0165","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1080\/02791072.2017.1361559","article-title":"Nourishing the Spirit: exploratory research on Ayahuasca experiences along the continuum of recovery from eating disorders","volume":"49","author":"Lafrance","year":"2017","journal-title":"J. Psychoactive Drugs"},{"issue":"33","key":"10.1016\/j.expneurol.2026.115822_bb0170","doi-asserted-by":"crossref","first-page":"eadx5958","DOI":"10.1126\/sciadv.adx5958","article-title":"N,N-dimethyltryptamine mitigates experimental stroke by stabilizing the blood-brain barrier and reducing neuroinflammation","volume":"11","author":"Laszlo","year":"2025","journal-title":"Sci. Adv."},{"issue":"8","key":"10.1016\/j.expneurol.2026.115822_bb0175","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23084148","article-title":"Biomarker of Neuroinflammation in Parkinson\u2019s disease","volume":"23","author":"Liu","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"1\u20133","key":"10.1016\/j.expneurol.2026.115822_bb0180","first-page":"46","article-title":"Pimavanserin in the treatment of Parkinson's disease psychosis: Meta-analysis and Meta-regression of randomized clinical trials","volume":"19","author":"Mansuri","year":"2022","journal-title":"Innov Clin Neurosci"},{"issue":"4","key":"10.1016\/j.expneurol.2026.115822_bb0185","doi-asserted-by":"crossref","DOI":"10.1038\/tp.2017.58","article-title":"The histamine H3 receptor antagonist thioperamide rescues circadian rhythm and memory function in experimental parkinsonism","volume":"7","author":"Masini","year":"2017","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.expneurol.2026.115822_bb0190","doi-asserted-by":"crossref","first-page":"208","DOI":"10.3389\/fneur.2018.00208","article-title":"Inhibition of mTORC1 signaling reverts cognitive and affective deficits in a mouse model of Parkinson's disease","volume":"9","author":"Masini","year":"2018","journal-title":"Front. Neurol."},{"issue":"6","key":"10.1016\/j.expneurol.2026.115822_bb0195","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines9060598","article-title":"A guide to the generation of a 6-Hydroxydopamine mouse model of Parkinson's disease for the study of non-motor symptoms","volume":"9","author":"Masini","year":"2021","journal-title":"Biomedicines"},{"key":"10.1016\/j.expneurol.2026.115822_bb0200","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/164_2017_15","article-title":"Sigma-1 (sigma(1)) receptor in memory and neurodegenerative diseases","volume":"244","author":"Maurice","year":"2017","journal-title":"Handb. Exp. Pharmacol."},{"issue":"8","key":"10.1016\/j.expneurol.2026.115822_bb0205","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1212\/WNL.38.8.1285","article-title":"Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson\u2019s and Alzheimer\u2019s disease brains","volume":"38","author":"McGeer","year":"1988","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.expneurol.2026.115822_bb0210","doi-asserted-by":"crossref","first-page":"18534","DOI":"10.1038\/s41598-023-45318-6","article-title":"Neuroprotective effects of polyacrylic acid (PAA) conjugated cerium oxide against hydrogen peroxide- and 6-OHDA-induced SH-SY5Y cell damage","volume":"13","author":"Meenambal","year":"2023","journal-title":"Sci. Rep."},{"key":"10.1016\/j.expneurol.2026.115822_bb0215","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/bs.mcb.2025.02.006","article-title":"Modeling neurodegeneration and neuroinflammation in Parkinson\u2019s disease: animal-based strategies","volume":"197","author":"Morales-Garcia","year":"2025","journal-title":"Methods Cell Biol."},{"issue":"2","key":"10.1016\/j.expneurol.2026.115822_bb0220","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1016\/j.neurobiolaging.2014.10.008","article-title":"Silencing phosphodiesterase 7B gene by lentiviral-shRNA interference attenuates neurodegeneration and motor deficits in hemiparkinsonian mice","volume":"36","author":"Morales-Garcia","year":"2015","journal-title":"Neurobiol. Aging"},{"issue":"2","key":"10.1016\/j.expneurol.2026.115822_bb0225","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1007\/s12035-019-01745-z","article-title":"Phosphodiesterase 7 regulation in cellular and rodent models of Parkinson\u2019s disease","volume":"57","author":"Morales-Garcia","year":"2020","journal-title":"Mol. Neurobiol."},{"issue":"1","key":"10.1016\/j.expneurol.2026.115822_bb0230","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1038\/s41398-020-01011-0","article-title":"N,N-dimethyltryptamine compound found in the hallucinogenic tea ayahuasca, regulates adult neurogenesis in vitro and in vivo","volume":"10","author":"Morales-Garcia","year":"2020","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.expneurol.2026.115822_bb0235","doi-asserted-by":"crossref","first-page":"419","DOI":"10.3389\/fphar.2019.00419","article-title":"Molecular interplay between the Sigma-1 receptor, steroids, and ion channels","volume":"10","author":"Morales-Lazaro","year":"2019","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.expneurol.2026.115822_bb0240","doi-asserted-by":"crossref","DOI":"10.1016\/j.expneurol.2020.113245","article-title":"N,N-dimethyltryptamine reduces infarct size and improves functional recovery following transient focal brain ischemia in rats","volume":"327","author":"Nardai","year":"2020","journal-title":"Exp. Neurol."},{"issue":"12","key":"10.1016\/j.expneurol.2026.115822_bb0245","doi-asserted-by":"crossref","first-page":"6625","DOI":"10.1007\/s12035-021-02488-6","article-title":"Sigma-1 receptor activation suppresses microglia M1 polarization via regulating endoplasmic reticulum-mitochondria contact and mitochondrial functions in stress-induced hypertension rats","volume":"58","author":"Ooi","year":"2021","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.expneurol.2026.115822_bb0250","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.nbd.2013.10.010","article-title":"Neuroprotective effects of the Sigma-1 receptor (S1R) agonist PRE-084, in a mouse model of motor neuron disease not linked to SOD1 mutation","volume":"62","author":"Peviani","year":"2014","journal-title":"Neurobiol. Dis."},{"issue":"13","key":"10.1016\/j.expneurol.2026.115822_bb0255","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1002\/mds.25945","article-title":"The prevalence of Parkinson\u2019s disease: a systematic review and meta-analysis","volume":"29","author":"Pringsheim","year":"2014","journal-title":"Mov. Disord."},{"issue":"12","key":"10.1016\/j.expneurol.2026.115822_bb0260","doi-asserted-by":"crossref","DOI":"10.3390\/biom12121745","article-title":"A focus on astrocyte contribution to Parkinson's disease etiology","volume":"12","author":"Prunell","year":"2022","journal-title":"Biomolecules"},{"issue":"7","key":"10.1016\/j.expneurol.2026.115822_bb0265","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1111\/acer.14635","article-title":"Antagonism of Sigma-1 receptor blocks heavy alcohol drinking and associated hyperalgesia in male mice","volume":"45","author":"Quadir","year":"2021","journal-title":"Alcohol. Clin. Exp. Res."},{"issue":"2\u20133","key":"10.1016\/j.expneurol.2026.115822_bb0270","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S0014-2999(97)00115-5","article-title":"Partial role of 5-HT2 and 5-HT3 receptors in the activity of antidepressants in the mouse forced swimming test","volume":"325","author":"Redrobe","year":"1997","journal-title":"Eur. J. Pharmacol."},{"issue":"2","key":"10.1016\/j.expneurol.2026.115822_bb0275","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.mcna.2018.10.014","article-title":"Parkinson\u2019s disease","volume":"103","author":"Reich","year":"2019","journal-title":"Med. Clin. North Am."},{"issue":"1","key":"10.1016\/j.expneurol.2026.115822_bb0280","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.cell.2009.01.038","article-title":"A Nurr1\/CoREST pathway in microglia and astrocytes protects dopaminergic neurons from inflammation-induced death","volume":"137","author":"Saijo","year":"2009","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.expneurol.2026.115822_bb0285","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s00702-021-02447-4","article-title":"Levodopa-induced dyskinesias in Parkinson\u2019s disease increase cerebrospinal fluid nitric oxide metabolites\u2019 levels","volume":"129","author":"Santos-Lobato","year":"2022","journal-title":"J. Neural Transm. (Vienna)"},{"issue":"3","key":"10.1016\/j.expneurol.2026.115822_bb0290","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/S0091-3057(03)00129-1","article-title":"Activities of extract and constituents of Banisteriopsis caapi relevant to parkinsonism","volume":"75","author":"Schwarz","year":"2003","journal-title":"Pharmacol. Biochem. Behav."},{"issue":"1","key":"10.1016\/j.expneurol.2026.115822_bb0295","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1021\/acsptsci.4c00564","article-title":"Sigma 1 receptor and its pivotal role in neurological disorders","volume":"8","author":"Shokr","year":"2025","journal-title":"ACS Pharmacol Transl Sci"},{"issue":"10","key":"10.1016\/j.expneurol.2026.115822_bb0300","doi-asserted-by":"crossref","first-page":"2925","DOI":"10.1007\/s11064-023-03960-6","article-title":"Targeting Sigma-1 receptor: a promising strategy in the treatment of Parkinson\u2019s disease","volume":"48","author":"Siddiqui","year":"2023","journal-title":"Neurochem. Res."},{"issue":"21","key":"10.1016\/j.expneurol.2026.115822_bb0305","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222111611","article-title":"Reduced GFAP expression in Bergmann glial cells in the cerebellum of Sigma-1 receptor knockout mice determines the neurobehavioral outcomes after traumatic brain injury","volume":"22","author":"Stelfa","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"6","key":"10.1016\/j.expneurol.2026.115822_bb0310","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1111\/ejn.12459","article-title":"Time course of dopamine neuron loss and glial response in the 6-OHDA striatal mouse model of Parkinson\u2019s disease","volume":"39","author":"Stott","year":"2014","journal-title":"Eur. J. Neurosci."},{"issue":"1","key":"10.1016\/j.expneurol.2026.115822_bb0315","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/s41531-022-00370-3","article-title":"Nitrosative stress in Parkinson\u2019s disease","volume":"8","author":"Stykel","year":"2022","journal-title":"NPJ Parkinsons Dis"},{"key":"10.1016\/j.expneurol.2026.115822_bb0320","doi-asserted-by":"crossref","first-page":"358","DOI":"10.3389\/fimmu.2015.00358","article-title":"Psychedelics and immunomodulation: novel approaches and therapeutic opportunities","volume":"6","author":"Szabo","year":"2015","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.expneurol.2026.115822_bb0325","doi-asserted-by":"crossref","first-page":"396","DOI":"10.4103\/1673-5374.179041","article-title":"Dimethyltryptamine (DMT): a biochemical Swiss Army knife in neuroinflammation and neuroprotection?","volume":"11","author":"Szabo","year":"2016","journal-title":"Neural Regen. Res."},{"issue":"8","key":"10.1016\/j.expneurol.2026.115822_bb0330","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0106533","article-title":"Psychedelic N,N-dimethyltryptamine and 5-methoxy-N,N-dimethyltryptamine modulate innate and adaptive inflammatory responses through the sigma-1 receptor of human monocyte-derived dendritic cells","volume":"9","author":"Szabo","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.expneurol.2026.115822_bb0335","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2021.108612","article-title":"N,N-Dimethyltryptamine attenuates spreading depolarization and restrains neurodegeneration by sigma-1 receptor activation in the ischemic rat brain","volume":"192","author":"Szabo","year":"2021","journal-title":"Neuropharmacology"},{"issue":"12","key":"10.1016\/j.expneurol.2026.115822_bb0340","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1007\/s00210-018-1551-z","article-title":"DPCPX, a selective adenosine A1 receptor antagonist, enhances the antidepressant-like effects of imipramine, escitalopram, and reboxetine in mice behavioral tests","volume":"391","author":"Szopa","year":"2018","journal-title":"Naunyn Schmiedeberg's Arch. Pharmacol."},{"issue":"12","key":"10.1016\/j.expneurol.2026.115822_bb0345","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0082930","article-title":"General anesthetics inhibit LPS-induced IL-1beta expression in glial cells","volume":"8","author":"Tanaka","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.expneurol.2026.115822_bb0350","doi-asserted-by":"crossref","first-page":"6","DOI":"10.3389\/fnsys.2013.00006","article-title":"Transcranial direct-current stimulation increases extracellular dopamine levels in the rat striatum","volume":"7","author":"Tanaka","year":"2013","journal-title":"Front. Syst. Neurosci."},{"issue":"1","key":"10.1016\/j.expneurol.2026.115822_bb0355","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.expneurol.2007.07.004","article-title":"Neuroinflammatory mechanisms in Parkinson\u2019s disease: potential environmental triggers, pathways, and targets for early therapeutic intervention","volume":"208","author":"Tansey","year":"2007","journal-title":"Exp. Neurol."},{"issue":"11","key":"10.1016\/j.expneurol.2026.115822_bb0360","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/s41577-022-00684-6","article-title":"Inflammation and immune dysfunction in Parkinson disease","volume":"22","author":"Tansey","year":"2022","journal-title":"Nat. Rev. Immunol."},{"issue":"6","key":"10.1016\/j.expneurol.2026.115822_bb0365","doi-asserted-by":"crossref","DOI":"10.1111\/acel.13031","article-title":"Oxidative stress in the aging substantia nigra and the etiology of Parkinson\u2019s disease","volume":"18","author":"Trist","year":"2019","journal-title":"Aging Cell"},{"issue":"1\u20132","key":"10.1016\/j.expneurol.2026.115822_bb0370","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.jchromb.2006.07.054","article-title":"Analysis of nitrite and nitrate in biological fluids by assays based on the Griess reaction: appraisal of the Griess reaction in the L-arginine\/nitric oxide area of research","volume":"851","author":"Tsikas","year":"2007","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci."},{"issue":"2","key":"10.1016\/j.expneurol.2026.115822_bb0375","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1038\/nprot.2006.116","article-title":"Morris water maze: procedures for assessing spatial and related forms of learning and memory","volume":"1","author":"Vorhees","year":"2006","journal-title":"Nat. Protoc."},{"issue":"7","key":"10.1016\/j.expneurol.2026.115822_bb0380","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1007\/s00210-019-01632-3","article-title":"Pharmacological stimulation of sigma-1 receptor promotes activation of astrocyte via ERK1\/2 and GSK3beta signaling pathway","volume":"392","author":"Wang","year":"2019","journal-title":"Naunyn Schmiedeberg\u2019s Arch. Pharmacol."},{"issue":"4","key":"10.1016\/j.expneurol.2026.115822_bb0385","doi-asserted-by":"crossref","first-page":"636","DOI":"10.2174\/1570159X22666231027111147","article-title":"The psychedelic future of post-traumatic stress disorder treatment","volume":"22","author":"Zaretsky","year":"2024","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.expneurol.2026.115822_bb0390","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.3389\/fphar.2019.01325","article-title":"The impact of Ayahuasca on suicidality: results from a randomized controlled trial","volume":"10","author":"Zeifman","year":"2019","journal-title":"Front. Pharmacol."}],"container-title":["Experimental Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001448862600186X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001448862600186X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T09:52:05Z","timestamp":1794563525000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S001448862600186X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":78,"alternative-id":["S001448862600186X"],"URL":"https:\/\/doi.org\/10.1016\/j.expneurol.2026.115822","relation":{},"ISSN":["0014-4886"],"issn-type":[{"value":"0014-4886","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic properties of ayahuasca component N,N-Dimethyltryptamine in a pre-clinical model of Parkinson's disease","name":"articletitle","label":"Article Title"},{"value":"Experimental Neurology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.expneurol.2026.115822","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"115822"}}